第3章 免疫抗體療法

第4章 融合抗體療法

第5章 複合標的及多官能抗體療法

第6章 專利期限和生技仿製藥的登場

簡介

該市場的生技仿製藥抗體

專利期限接近的標靶產品

生技改良藥預測

修飾抗體的明亮未來

摘要

第7章 交易與市場

合併、收購

全合併的起源

摘要

第8章 策略性課題

基礎研究和臨床研究的調整

腫瘤學的新方法:診斷和治療

機會及陷阱

摘要

第9章 對該領域專家的採訪

第10章 抗體技術的發展相關產業相關人員詢問調查

參考資訊

關於Cambridge Healthtech Institute

圖表

目錄

Recombinant antibodies have been the shining jewels in the firmament of the pharma industry for almost the last two decades. They have returned billions of dollars in sales, and if their performance has not been the unalloyed triumph that was foreseen at their inception, they have, at least in some instances, produced impressive gains in patient response. Today they are one of the most fundamental strategies for treating patients with hematological malignancies and solid tumors. This report explores the next level of therapy, combining antibodies with additional agents.

The report consists of eight chapters that address different aspects of the issue of combined antibody therapy - past, present, and future, topics include:

A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy